OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 9 of 19

10 Prescribing Obesity Medications Medications Approved for Long-Term Treatment of Obesity Drug How Taken Main Side Effects Orlistat By mouth (PO) three times daily, with fat-containing meals Gastrointestinal (GI) lipase inhibitor (fat absorption) Naltrexone/bupropion ER Two pills PO twice daily; avoid high-fat meals Opioid antagonist + norepinephrine- dopamine reuptake inhibitor (NDRI) Phentermine/topiramate ER PO every morning Sympathomimetic + topiramate Liraglutide Subcutaneous daily GLP-1 RA Semaglutide Subcutaneous weekly; PO daily, taken alone on an empty stomach with no other PO intake for 30 min GLP-1 RA Tirzepatide Subcutaneous weekly Dual GLP-1/GIP RA

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026